ERBB2 and neoplasm: Currently, there is growing evidence that patients with high levels of immune infiltration may benefit more from the anti-HER2 monoclonal antibody trastuzumab [4,5], indicating that tumor-infiltrating lymphocytes (TILs) might serve as a biomarker of anti-HER2 therapeutic response.